These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 9198226)
1. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Landolfi R; Marchioli R; Patrono C Thromb Haemost; 1997 Jul; 78(1):617-21. PubMed ID: 9198226 [TBL] [Abstract][Full Text] [Related]
2. Aspirin in essential thrombocythemia: status quo and quo vadis. Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354 [TBL] [Abstract][Full Text] [Related]
3. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. Landolfi R; Di Gennaro L; Novarese L; Patrono C Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279 [TBL] [Abstract][Full Text] [Related]
4. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569 [TBL] [Abstract][Full Text] [Related]
5. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Landolfi R; Cipriani MC; Novarese L Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491 [TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274 [TBL] [Abstract][Full Text] [Related]
7. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Elliott MA; Tefferi A Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529 [TBL] [Abstract][Full Text] [Related]
8. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599 [TBL] [Abstract][Full Text] [Related]
9. Bleeding and thrombosis in myeloproliferative disorders. Landolfi R Curr Opin Hematol; 1998 Sep; 5(5):327-31. PubMed ID: 9776211 [TBL] [Abstract][Full Text] [Related]
10. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Michiels JJ Pathol Biol (Paris); 2003 Apr; 51(3):167-75. PubMed ID: 12781799 [TBL] [Abstract][Full Text] [Related]
11. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Murphy S Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227 [TBL] [Abstract][Full Text] [Related]
13. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Landolfi R; Marchioli R Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206 [TBL] [Abstract][Full Text] [Related]
14. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Wehmeier A; Südhoff T; Meierkord F Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357 [TBL] [Abstract][Full Text] [Related]
15. [Thrombosis and platelet dysfunction in myeloproliferative neoplasms]. Mornet C; Galinat H; Mingant F; Ianotto JC; Lippert E Rev Med Interne; 2020 May; 41(5):319-324. PubMed ID: 32008800 [TBL] [Abstract][Full Text] [Related]
17. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Petrides PE; Siegel F Blood Cells Mol Dis; 2006; 36(3):379-84. PubMed ID: 16563815 [TBL] [Abstract][Full Text] [Related]
18. Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin. Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; van Vliet HH Blood Cells Mol Dis; 2006; 36(2):199-205. PubMed ID: 16510297 [TBL] [Abstract][Full Text] [Related]
19. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Finazzi G; Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715 [TBL] [Abstract][Full Text] [Related]
20. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. Levy Y; Shenkman B; Tamarin I; Pauzner R; Shoenfeld Y; Langevitz P; Savion N; Varon D Arthritis Rheum; 2005 Dec; 52(12):4011-7. PubMed ID: 16320349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]